Valuation: Biogen Inc.

Market Cap 31B 161B 26.77B 25.11B 22.87B 43B 2,964B 43.6B 294B 115B 1,485B 116B 114B 4,940B P/E 2026 *
37.3x
P/E 2027 * 18.4x
Enterprise Value 35.94B 186B 31.03B 29.11B 26.51B 49.85B 3,436B 50.54B 341B 134B 1,722B 135B 132B 5,727B EV / Sales 2026 *
3.44x
EV / Sales 2027 * 3.14x
Free-Float
85.97%
Yield 2026 *
-
Yield 2027 * -
1 day+1.41%
1 month+1.41%
3 months+6.48%
6 months+0.28%
Current year+7.30%
1 month 169.32
Extreme 169.32
172.75
Current year 147.5
Extreme 147.5
187.2
1 year 120.36
Extreme 120.36
187.2
3 years 110.07
Extreme 110.07
225
5 years 110.07
Extreme 110.07
313.69
10 years 110.07
Extreme 110.07
360
Manager TitleAgeSince
Chief Executive Officer 66 14/11/2022
Director of Finance/CFO 60 01/03/2025
Chief Tech/Sci/R&D Officer - 28/10/2024
Director TitleAgeSince
Director/Board Member 69 23/03/2010
Director/Board Member 77 01/01/2010
Director/Board Member 72 19/06/2019
Change 5-day change 1-year change 3-year change Capi.($)
+1.41%-.--% - - 31B
+0.30%-0.26%+40.43%+1.15% 80.23B
-1.02%-0.51%-2.54%+28.91% 50.64B
+1.46%-3.45%+11.90%+164.29% 46.87B
-1.39%+1.82%-50.22%-50.44% 46.34B
-0.32%+0.98%+53.89%-20.02% 31B
+1.80%+7.77%+129.48%-39.33% 25.28B
+2.78%+1.60%+45.43%+92.34% 24.36B
+1.65%+0.53%-2.21%+190.26% 20.81B
+3.95%+1.02%+67.20%+117.59% 16.08B
Average +1.04%+0.35%+32.60%+53.86% 37.96B
Weighted average by Cap. +0.57%+0.53%+24.68%+39.24%

Financials

2026 *2027 *
Net sales 10.44B 54.13B 9.01B 8.46B 7.7B 14.48B 998B 14.68B 99.14B 38.85B 500B 39.2B 38.36B 1,664B 10.66B 55.25B 9.2B 8.63B 7.86B 14.78B 1,019B 14.99B 101B 39.66B 511B 40.02B 39.15B 1,698B
Net income 953M 4.94B 823M 772M 703M 1.32B 91.13B 1.34B 9.05B 3.55B 45.65B 3.58B 3.5B 152B 1.9B 9.84B 1.64B 1.54B 1.4B 2.63B 182B 2.67B 18.03B 7.07B 90.98B 7.13B 6.98B 303B
Net Debt 4.94B 25.59B 4.26B 4B 3.64B 6.85B 472B 6.94B 46.87B 18.37B 236B 18.53B 18.13B 787B 2.42B 12.54B 2.09B 1.96B 1.79B 3.36B 231B 3.4B 22.98B 9B 116B 9.09B 8.89B 386B
Logo Biogen Inc.
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows: - sales of medicines (72%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.; - royalties (7.4%) ; - other (20.6%): primarily revenues from partnership agreements.
Employees
7,500
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
35
Last Close Price
209.83USD
Average target price
235.57USD
Spread / Average Target
+12.27%

Quarterly revenue - Rate of surprise